Fusians Biomedicals, Inc., has signed an exclusive license agreement with
the University of Alabama at Birmingham Research Foundation to further develop
their fusion inhibitors ......
Fuzians Biomedicals, Inc.,
is a world leader in pharmaceutical development industry. Fuzian is
dedicated to innovative design of novel pharmaceuticals by combination of
state-of-the-art biomedical and chemical technologies. The focus of Fuzian
is viral diseases which are among the leading causes of death in the
United States and the world. Currently there are a limited number of
antiviral classes that target different mechanisms of virus replication.
It has been recognized that the most effective treatment for viral
diseases is the combination therapy that simultaneously